Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 6 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 5 days ago
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

Adjuvant nivolumab bests ipilimumab in surgically resected melanoma

Jenny Ng
22 Sep 2017
Dr Jeffrey Weber

Adjuvant nivolumab treatment significantly improved outcomes vs ipilimumab in patients with surgically resected stage III/IV melanoma, according to interim results of the CheckMate 238 trial.

In the trial, nivolumab significantly improved the rate of relapse-free survival (RFS) vs ipilimumab (hazard ratio [HR], 0.65; p<0.0001) and was associated with substantially fewer adverse events. [N Engl J Med 2017, doi: 10.1056/NEJMoa1709030]

The results suggest that the PD-1 inhibitor nivolumab may be a new standard treatment option for patients with resected stage III/IV melanoma. CheckMate 238 was stopped early due to a clear benefit in the nivolumab arm.

“Nivolumab clearly showed a very clinically and statistically significant improvement in RFS vs high-dose ipilimumab for these patients,” said investigator Dr Jeffrey Weber of the New York University Langone Medical Center in New York City, US, who presented the results at the European Society for Medical Oncology (ESMO) 2017 Congress. “The benefit of nivolumab was observed in virtually all of the prespecified subgroups, whether you look at disease stage, PD-L1 staining, BRAF mutation status, age, or ulceration of the primary tumour.”

Both nivolumab and the CTLA-4 inhibitor ipilimumab are approved for the treatment of patients with advanced melanoma. Ipilimumab was approved for adjuvant treatment of patients with stage III resected melanoma in the US in 2015. However, its use is still debated due to concerns over its high level of toxicity.

CheckMate 238 was a phase III, randomized, double-blind clinical trial that included 906 patients with completely resected stage IIIB, IIIC or IV melanoma with a >50 percent risk of relapse over 5 years. Patients were randomized to receive either nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for four doses and then once every 12 weeks.

At the 18-month interim follow-up, the rate of RFS was 66.4 percent in the nivolumab arm vs 52.7 percent in the ipilimumab arm. In subgroup analyses, the 12-month RFS rate in patients with PD-L1 expression level ≥5 percent was 81.9 percent in the nivolumab arm vs 73.8 percent in the ipilimumab arm, while the RFS rate in patients with PD-L1 expression level <5 percent was 64.3 vs 53.7 percent. The exploratory endpoint of distant metastasis-free survival was also significantly improved in the nivolumab vs ipilimumab arm (HR, 0.73; p=0.02).

Importantly, rates of grade 3/4 adverse events were substantially lower with nivolumab vs ipilimumab. Treatment-related grade 3/4 adverse events occurred in 14.4 percent of patients receiving nivolumab vs 45.9 percent of patients receiving ipilimumab. Moreover, fewer patients receiving nivolumab had to discontinue treatment due to any adverse events compared with those receiving ipilimumab (9.7 vs 42.6 percent).

“In my opinion, nivolumab provides a very acceptable risk-benefit ratio as adjuvant therapy for high-risk resected melanoma. It has the potential to be an effective treatment option for patients with resected stage III and IV disease,” Weber said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 6 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 5 days ago
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).